Publication | Open Access

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Neuro-oncologyPrimary Vitreoretinal LymphomaLymphoid NeoplasiaOphthalmologyMedicineLymphoma Study AssociationNeurologyNeuroimmunologyIbrutinib Monotherapy